What do you recommend for fertility preservation in pediatric patients with impending cyclophosphamide use for treatment of a rheumatic disease?

Cyclophosphamide (CYC) is an alkylating agent primarily used in the treatment of malignant lymphomas, and its gonadotoxic properties are well-established. CYC can cause ovarian toxicity via follicle atresia and granulosa cell apoptosis in females as well as oligospermia and azoospermia in males. In ...

Fertility preservation, in the work I have done, is overlooked, or if addressed, not carried through in the majority of pediatric rheumatology patients receiving cyclophosphamide. This is very multifactorial however as to why. In the United States, there are numerous barriers to rheumatic disease pa...

I am not a pediatric rheumatologist so I would need to defer to a pediatric rheumatologist regarding this question. However, the Euro lupus protocol 500mg q two weeks x 6, has not been shown to significantly reduce fertility. Moreover, impairment of ovarian function after cyclophosphamide therapy is...